24小时热门版块排行榜    

CyRhmU.jpeg
查看: 455  |  回复: 1

xunmeng0011

铁杆木虫 (正式写手)

[求助] 求助硼替佐米(179324-69-7)的默克索引

求助硼替佐米(179324-69-7)的默克索引,谢谢!
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

baiyuefei

版主 (文学泰斗)

风雪

优秀版主优秀版主优秀版主文献杰出贡献优秀版主优秀版主优秀版主文献杰出贡献优秀版主优秀版主优秀版主优秀版主文献杰出贡献优秀版主优秀版主优秀版主优秀版主优秀版主优秀版主

【答案】应助回帖

★ ★ ★ ★ ★ ★ ★ ★ ★ ★
xunmeng0011: 金币+10, ★★★★★最佳答案, 谢谢! 2013-11-12 08:46:21
Title: Bortezomib
CAS Registry Number: 179324-69-7
CAS Name: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
Additional Names: N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
Manufacturers' Codes: MG-341; PS-341
Trademarks: Velcade (Millenium)
Molecular Formula: C19H25BN4O4
Molecular Weight: 384.24
Percent Composition: C 59.39%, H 6.56%, B 2.81%, N 14.58%, O 16.66%
Literature References: Dipeptide boronic acid proteasome inhibitor. Prepn: J. Adams et al., WO 9613266; eidem, US 5780454 (1996, 1998 both to ProScript); idem et al., Bioorg. Med. Chem. Lett. 8, 333 (1998). Pharmacology and cytotoxic activity: idem et al., Cancer Res. 59, 2615 (1999). Crystal structure in complex with the yeast 20S proteasome: M. Groll et al., Structure 14, 451 (2006). Mechanism of action study: J. Codony-Servat et al., Mol. Cancer Ther. 5, 665 (2006). Clinical trial in refractory myeloma: P. G. Richardson et al., N. Engl. J. Med. 348, 2609 (2003). Review of clinical development: idem et al., Annu. Rev. Med. 57, 33-47 (2006).
Properties: Soly in water: 3.3-3.8 mg/ml (pH 2-6.5).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic.
2楼2013-11-11 19:03:54
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 xunmeng0011 的主题更新
信息提示
请填处理意见